Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | OXTR | P30559 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ALPL | P05186 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14415777 | 0.90 | CES2 (0.50) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL4438678 | 0.89 | MAPK14 (0.60) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL11114080 | 0.86 | MAPK13 (0.55) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL11107952 | 0.84 | LMNA (0.45) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL11101475 | 0.84 | PTGS2 (0.51) | MAPK14KMT2AMEN1NPC1POLB | |
| SCHEMBL29387256 | 0.82 | CYP3A4 (0.55) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL333141 | 0.82 | CYP3A4 (0.55) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL11753699 | 0.81 | TSHR (0.51) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL10669335 | 0.80 | CYP3A4 (0.59) | MAPK14MAPK13MAPK12MAPK11KMT2A | |
| SCHEMBL1584375 | 0.79 | KMT2A (0.56) | MAPK14MAPK13MAPK12MAPK11KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061754-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008115999-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | XENON PHARMACEUTICALS INC. (CA) | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234384-A1 | BIARYL AND BIHETEROARYL COMPOUNDS USEFUL IN TREATING IRON DISORDERS | FECH, SLC10A1, SLC40A1 | MAPK14 3985/4885MAPK13 2350/4885MAPK12 2749/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.